New Beacon platform data to be presented by
Genovac at Discovery on Target 2023
Poster and podium presentation featuring the
Beacon platform to be presented at Annual Festival of Biologics
Basel Conference & Exhibition
EMERYVILLE,
Calif., Sept. 20, 2023 /PRNewswire/ -- PhenomeX
Inc. (Nasdaq: CELL), a functional cell biology company, today
announced it will showcase their latest optofluidic and proteomic
technologies, along with customer partners, at two upcoming cell
biology conferences.
Discovery on Target 2023 Conference
Genovac, a top contract research and
manufacturing organization and a long-standing customer of PhenomeX
and super user of the Beacon optofluidic technology, will lead a
presentation at the Discovery on Target 2023 conference being
held from September 25-27, 2023 in
Boston. The Discovery on Target
conference is the industry's preeminent event on novel drug targets
and technologies.
Andreas Weise,
senior account manager at Genovac, will deliver a presentation
featuring PhenomeX's Beacon platform entitled "Enhance and Expand
Anti-ID Antibody Diversity and Affinity Through Genetic
Immunization."
Date: Tuesday, September
26 from 2:20 p.m. - 2:50 p.m.
ET
Abstract: Learn how Genovac identified and
characterized highly diverse high-affinity anti-idiotypic
antibodies that enable candidate therapeutic antibody PK/PD studies
by leveraging their cutting-edge immunization strategies and
world-class expertise in adapting new animal species onto
PhenomeX's optofluidic single B cell screening on the Beacon
platform.
Annual Festival of Biologics Basel Conference
& Exhibition
PhenomeX will participate in The Festival of
Biologics conference held from October
10-12, 2023, in Basel,
Switzerland. The Festival of Biologics brings together
pharma, biotech, and academic and research institutes, as well as
their partners across the value chain in the areas of antibodies,
immunotherapy and biosimilars.
PhenomeX will feature its optofluidic and
proteomic technologies at the conference in booth #910, and
attendees can explore demonstrations and learn more about how
PhenomeX's products can advance and accelerate our understanding of
cellular function along the continuum of scientific discovery,
bioprocessing, clinical research, and immunotherapy
development.
PhenomeX technology is highlighted in a poster
presentation entitled "Rapid Discovery of Functional Human Memory B
Cell-Derived Antibodies for SARS-CoV-2 Using the Beacon Optofluidic
System."
In addition, PhenomeX will lead a presentation
highlighting how optofluidics can accelerate antibody discovery
workflows.
Jonathan Didier,
senior field applications scientist at PhenomeX, will present:
"Rapid Discovery of Clinically Relevant Antibodies using the
PhenomeX Beacon," as part of the Cell Culture & Upstream
Processing conference track.
Date: October 11,
2023 from 4:50 p.m. –
5:10 p.m. CET
Abstract: Opto® Plasma B
Discovery Workflows on the Beacon optofluidic systems offer
customers an attractive alternative in rapid function-first
screening that allows antibody discovery in multiple species and
physiologically relevant repertoires without significant investment
or limitations that exist in hybridoma or phage display. In this
presentation, participants will learn how PhenomeX and its
customers have used existing Opto Plasma B Discovery products and
protocols to accelerate antibody discovery for their clients, and
how these were adapted to different species to achieve a broader
sequence diversity to meet client objectives.
About PhenomeX Inc.
PhenomeX is empowering scientists to leverage the
full potential of each cell and drive the next era of functional
cell biology that will advance human health. We enable scientists
to reveal the most complete insights on cell function and obtain a
full view of the behavior of each cell. Our unique suite of proven
high-throughput tools and services offer unparalleled resolution
and speed, accelerating the insights that are key to advancing
discoveries that can profoundly improve the prevention and
treatment of disease. Our award-winning platforms are used by
researchers across the globe, including those at the top 15 global
pharmaceutical companies and approximately 85% of leading U.S.
comprehensive cancer centers.
PhenomeX has no affiliation with Phenomenex, Inc.
PhenomeX will be changing its name. All inquiries regarding
Phenomenex, Inc. and/or its products should be directed
to info@phenomenex.com.
Forward-Looking Statements
To the extent that statements contained in this
press release are not descriptions of historical facts regarding
PhenomeX or its products, they are forward-looking statements
reflecting the current beliefs and expectations of management. Such
forward-looking statements involve substantial known and unknown
risks and uncertainties that relate to future events, and actual
results and product performance could differ significantly from
those expressed or implied by the forward-looking statements.
PhenomeX undertakes no obligation to update or revise any
forward-looking statements. For a further description of the risks
and uncertainties relating to the Company's growth and continual
evolution see the statements in the "Risk Factors" sections, and
elsewhere, in our filings with the U.S. Securities and Exchange
Commission.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/phenomex-to-participate-in-upcoming-cell-biology-conferences-301933432.html
SOURCE PhenomeX